Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaki Ri

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
International Journal of Hematology|June 14, 2022
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myelomaSatsuki Murakami, Masaki Ri, Masato Ito, et al.
Cancer Medicine|April 27, 2023
Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasiaTomotaka Suzuki, Shigeru Kusumoto, Yoshiko Kamezaki, et al.
International Journal of Hematology|February 15, 2023
A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphomaTomotaka Suzuki, Shigeru Kusumoto, Yoshiko Kamezaki, et al.
Cancer Science|September 25, 2020
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy studyKazutaka Sunami, Kenshi Suzuki, Masaki Ri, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 27, 2025
[Development and performance evaluation of a comprehensive genomic profiling assay for hematological malignancies]Yasunori Kogure, Yuji Oshikawa-Kumade, Suguru Fukuhara, et al.
Leukemia Research|November 12, 2013
Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myelomaAtsushi Inagaki, Emi Tajima, Miyuki Uranishi, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 4, 2023
[Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy]Tomoyasu Jo, Tomoko Henzan, Daisuke Tomizawa, et al.
Blood|March 1, 2024
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasoneYasunori Kogure, Hiroshi Handa, Yuta Ito, et al.
British Journal of Haematology|May 10, 2020
Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohortTakashi Kanamori, Masashi Sanada, Masaki Ri, et al.
Ejhaem|September 2, 2022
Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in JapanYurie Miyamoto-Nagai, Naoya Mimura, Nobuhiro Tsukada, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
International Journal of Hematology|June 14, 2022
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myelomaSatsuki Murakami, Masaki Ri, Masato Ito, et al.
Cancer Medicine|April 27, 2023
Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasiaTomotaka Suzuki, Shigeru Kusumoto, Yoshiko Kamezaki, et al.
International Journal of Hematology|February 15, 2023
A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphomaTomotaka Suzuki, Shigeru Kusumoto, Yoshiko Kamezaki, et al.
Cancer Science|September 25, 2020
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy studyKazutaka Sunami, Kenshi Suzuki, Masaki Ri, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 27, 2025
[Development and performance evaluation of a comprehensive genomic profiling assay for hematological malignancies]Yasunori Kogure, Yuji Oshikawa-Kumade, Suguru Fukuhara, et al.
Leukemia Research|November 12, 2013
Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myelomaAtsushi Inagaki, Emi Tajima, Miyuki Uranishi, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 4, 2023
[Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy]Tomoyasu Jo, Tomoko Henzan, Daisuke Tomizawa, et al.
Blood|March 1, 2024
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasoneYasunori Kogure, Hiroshi Handa, Yuta Ito, et al.
British Journal of Haematology|May 10, 2020
Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohortTakashi Kanamori, Masashi Sanada, Masaki Ri, et al.
Ejhaem|September 2, 2022
Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in JapanYurie Miyamoto-Nagai, Naoya Mimura, Nobuhiro Tsukada, et al.
Pageof 12